Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Medtronic
Queensland Health
Teva
McKinsey
Johnson and Johnson
Citi
Harvard Business School
McKesson
Cerilliant

Generated: February 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,589,960

« Back to Dashboard

Summary for Patent: 6,589,960
Title: Hydromorphone and hydrocodone compositions and methods for their synthesis
Abstract:A method for the preparation of a ketone from a narcotic alkaloid having an allyl alcohol moiety is disclosed. The method includes mixing the narcotic alkaloid with an acid in the presence of a catalyst wherein the method is carried out in the substantial absence of hydrogen gas. The method is useful for preparing hydromorphone and hydrocodone compositions having novel impurity profiles. Compositions comprising hydromorphone and hydrocodone are also disclosed.
Inventor(s): Harclerode; William H. (Asbury, NJ), Gault; Robert (Gross Pointe Woods, MI), Sandison; Mark D. (Dearborn, MI)
Assignee: Abbott Laboratories (Abbott Park, IL)
Application Number:10/256,996
Patent Claim Types:
see list of patent claims
Composition; Process; Use;

Drugs Protected by US Patent 6,589,960

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Purdue Pharma Lp PALLADONE hydromorphone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021044-001 Sep 24, 2004 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Purdue Pharma Lp PALLADONE hydromorphone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021044-002 Sep 24, 2004 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Purdue Pharma Lp PALLADONE hydromorphone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021044-003 Sep 24, 2004 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Purdue Pharma Lp PALLADONE hydromorphone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 021044-004 Sep 24, 2004 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Fresenius Kabi Usa DILAUDID hydromorphone hydrochloride INJECTABLE;INJECTION 019034-003 Apr 30, 2009 AP RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Fresenius Kabi Usa DILAUDID hydromorphone hydrochloride INJECTABLE;INJECTION 019034-004 Apr 30, 2009 AP RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Fresenius Kabi Usa DILAUDID hydromorphone hydrochloride INJECTABLE;INJECTION 019034-005 Apr 30, 2009 AP RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Fresenius Kabi Usa DILAUDID-HP hydromorphone hydrochloride INJECTABLE;INJECTION 019034-001 Jan 11, 1984 AP RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Fresenius Kabi Usa DILAUDID-HP hydromorphone hydrochloride INJECTABLE;INJECTION 019034-002 Aug 4, 1994 DISCN No No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Rhodes Pharms DILAUDID hydromorphone hydrochloride SOLUTION;ORAL 019891-001 Dec 7, 1992 AA RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,589,960

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,512,117 Hydromorphone and hydrocodone compositions and methods for their synthesis ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,589,960

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 402937 ➤ Sign Up
Austria 500257 ➤ Sign Up
Australia 1595701 ➤ Sign Up
Canada 2389193 ➤ Sign Up
Canada 2674424 ➤ Sign Up
Canada 2854796 ➤ Sign Up
Germany 60039711 ➤ Sign Up
Germany 60045695 ➤ Sign Up
European Patent Office 1233966 ➤ Sign Up
European Patent Office 2003134 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
UBS
Cantor Fitzgerald
US Army
Fuji
Colorcon
McKesson
Chinese Patent Office
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot